Zymeworks Inc (NASDAQ: ZYME) is a clinical-stage biopharmaceutical company that develops multispecific antibody therapeutics and antibody-drug conjugates for oncology. Revenue is generated through royalties, milestones, and partnership agreements tied to its proprietary technology platforms and drug candidates. The company's core platform, Azymetric, enables the engineering of bispecific and trispecific antibodies by transforming monospecific antibodies through proprietary amino acid substitutions. The FDA approval of zanidatamab in 2024 validated the Azymetric platform. Additional platforms include TriTCE and ProTECT, which can be combined with Azymetric to develop trispecific therapeutics. Zymeworks relies on third-party manufacturers for drug supply and contract research organizations for clinical trials. As of December 31, 2025, the company had an active $125.0 million share repurchase program authorized in November 2025, under which 431,217 shares had been repurchased.

Revenue model

Revenue is derived from royalties and milestone payments from strategic partners, tied to the development and commercialization of drug candidates built on Zymeworks' proprietary platforms, including Azymetric, TriTCE, and ProTECT. The company does not appear to have commercial product sales of its own as of the filing date; revenue is partnership- and licensing-dependent.

Products and services

Core platforms include the Azymetric multispecific antibody platform (enabling bispecific and trispecific antibody engineering), the TriTCE T-cell engager technology, and the ProTECT platform. Zanidatamab, a bispecific antibody built on Azymetric, received FDA approval in 2024. The company also develops antibody-drug conjugates using the Azymetric backbone.

Customers and end markets

End markets are oncology therapeutics. Customers are primarily strategic pharmaceutical partners who license or co-develop drug candidates using Zymeworks' platforms. Patient populations targeted are cancer patients addressable by bispecific and trispecific antibody therapies.

Value-chain role

Zymeworks occupies a drug discovery and development role, providing proprietary antibody engineering platforms and conducting clinical-stage development. Manufacturing is fully outsourced to third-party contract manufacturers. Clinical trials are conducted through third-party contract research organizations.

Geographic exposure

Zymeworks conducts clinical trials outside the United States through third-party partners. Its intellectual property strategy prioritizes the United States, with acknowledged limitations on patent enforcement in certain international jurisdictions.

Source: SEC 10-K, filed 2026-03-02

Industry: Pharmaceutical Preparations Peers: Aurinia Pharmaceuticals Inc ESSA Pharma Inc. Fusion Pharmaceuticals Inc. Repare Therapeutics Inc. Xenon Pharmaceuticals Inc